Genovis AB (OSTO:GENO) Margin of Safety % (DCF Earnings Based): N/A (As of Jun. 27, 2026)


OSTO:GENO Genovis AB OSTO:GENO
84 GF Score
Price kr19.46
GF Value kr28.45
Valuation Significantly Undervalued
! 3 Warning Signs
View Full Analysis

What is Genovis AB Margin of Safety % (DCF Earnings Based)?

Margin of Safety % (DCF Earnings Based) = (Intrinsic Value: DCF (Earnings Based) - Current Price) / Intrinsic Value: DCF (Earnings Based).

Note: Discounted Earnings model is only suitable for predictable companies (Business Predictability Rank higher than 1-Star). If the company's Predictability Rank is 1-Star or Not Rated, result may not be accurate due to the low predictability of business and the data will not be stored into our database.

Genovis AB's Predictability Rank is 1-Star. Thus, the DCF related results in the screener and portfolio will appear as zero and Margin of Safety % (DCF Earnings Based) is not calculated.

OSTO:GENO vs VRTX, REGN, ALNY: Margin of Safety % (DCF Earnings Based) Comparison

For the Biotechnology subindustry, Genovis AB's Margin of Safety % (DCF Earnings Based), along with its competitors' market caps and Margin of Safety % (DCF Earnings Based) data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Genovis AB Margin of Safety % (DCF Earnings Based) vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Genovis AB's Margin of Safety % (DCF Earnings Based) distribution charts can be found below:

* The bar in red indicates where Genovis AB's Margin of Safety % (DCF Earnings Based) falls into.


OSTO:GENO
84GF Score
Genovis AB OSTO:GENO
Margin of Safety % (DCF Earnings Based) is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Genovis AB (OSTO:GENO) Overvalued in 2026?

Based on GuruFocus' analysis, Genovis AB stock appears to be undervalued. The current stock price of kr19.46 is trading 31.6% below its estimated GF Value™ of kr28.45. GuruFocus considers Genovis AB to be Significantly Undervalued.

Key valuation signals for OSTO:GENO:

  • Margin of Safety % (DCF Earnings Based): N/A
  • GF Value™: kr28.45 vs. price of kr19.46 (31.6% below fair value)
  • GF Score™: 84/100 with 3 warning signs

No single metric tells the full story. See the OSTO:GENO stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Genovis AB Business Description

Address Kavlinge, Box 4, Lund, SWE, SE-24421
Genovis AB offers customers in the biopharmaceutical and research industries tools that facilitate and save time in the development of new treatment methods and diagnostics. Its enzyme products, known as SmartEnzymes, are used by scientists all over the world, and the product formats facilitate the development and quality control of biological drugs. Its products include Enzyme and Antibodies. Geographically, it operates in Sweden and Rest of the world.
84GF Score

Get the complete analysis for OSTO:GENO

Margin of Safety % (DCF Earnings Based) is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

kr19.46
Price
kr28.45
GF Value